![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pfizer Signs Agreement With Schering AG to License Compounds
Pfizer Signs Agreement With Schering AG to License Compounds
Pfizer and Schering AG have signed a license agreement granting Pfizer a worldwide
license to Schering AG's ADP receptor antagonist program. Under the agreement,
Pfizer will have exclusive rights to develop and market oral antiplatelet compounds
developed by Schering AG's U.S. affiliate Berlex. Schering will receive an upfront
fee, milestone payments and royalties on sales of any compounds successfully
commercialized under the agreement. Specific financial terms were not announced.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct